Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aldeyra Therapeu
(NQ:
ALDX
)
5.570
+0.340 (+6.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aldeyra Therapeu
< Previous
1
2
3
4
5
6
Next >
Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
June 23, 2023
From
Aldeyra Therapeutics
Via
Business Wire
Aldeyra Therapeutics Provides Regulatory Update on ADX-2191
June 21, 2023
From
Aldeyra Therapeutics
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis
June 14, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
June 02, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
May 04, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
May 02, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
April 13, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) Records 52-Week High Monday Morning
April 10, 2023
Via
Investor Brand Network
Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis
April 06, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough
March 30, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa
March 16, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
March 09, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma
March 02, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights
March 01, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
February 28, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
February 23, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
February 16, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
February 09, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
February 07, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma
December 21, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial
December 13, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA
December 01, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease
November 29, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights
November 10, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
November 03, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting
October 26, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
October 06, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
October 05, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones
September 14, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
September 07, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.